Lv5
1140 积分 2021-09-09 加入
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
12天前
已完结
Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemia
12天前
已完结
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
12天前
已完结
Germline mutations in MDS/AML predisposition disorders
12天前
已完结
Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy
16天前
已完结
Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature Review
19天前
已完结
Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia
23天前
已完结
Common Leukemia- and Lymphoma-Associated Genetic Aberrations in Healthy Individuals
23天前
已完结
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
23天前
已完结
Minimal residual disease monitoring by quantitative RT‑PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML‑15 trial
23天前
已关闭
皖公网安备34019202002308
